Gilead Sciences »

Xilio Therapeutics shares owned by Gilead Sciences

Quarter-by-quarter ownership of Xilio Therapeutics (XLO) shares owned by Gilead Sciences from 13F filings

Historical chart of Gilead Sciences investment in Xilio Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Xilio Therapeutics held by Gilead Sciences consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Xilio Therapeutics by Gilead Sciences

Quarter filed Position value Share count Share price at filing
2024-12-31 $8.7M 9.1M 0.96

More positions owned by Gilead Sciences

Arcellx Common Stock (ACLX)
Galapagos Nv Spon Adr (GLPG)
Arcus Biosciences Incorporated (RCUS)
Assembly Biosciences Com New (ASMB)
Merus N V (MRUS)
Kyverna Therapeutics (KYTX)
Leap Therapeutics Com New (LPTX)
Tango Therapeutics (TNGX)
Xilio Therapeutics (XLO)
Allovir (ALVR)
Hookipa Pharma Com New (HOOK)
Ikena Oncology (IKNA)
Allogene Therapeutics (ALLO)
Barinthus Biotherapeutics Pl Ads (BRNS)
Agenus Com New (AGEN)

View all positions for Gilead Sciences

Top funds holding Xilio Therapeutics

Gilead Sciences
Bain Capital Life Sciences Investors
Rock Springs Capital Management
RiverVest Venture Management
FMR
Morgan Stanley
Vanguard Group
Geode Capital Management
Balyasny Asset Management
Renaissance Technologies
Trustees of Columbia University in the City of New York
UBS Group
Fil
BlackRock
Bridgeway Capital Management

View all funds holding Xilio Therapeutics